Bolt Biotherapeutics, Inc. (NASDAQ:BOLT - Get Free Report) major shareholder Coastlands Capital Lp acquired 20,000 shares of the company's stock in a transaction dated Tuesday, November 17th. The shares were bought at an average price of $5.75 per share, for a total transaction of $115,000.00. Following the acquisition, the insider owned 515,510 shares in the company, valued at approximately $2,964,182.50. This trade represents a 4.04% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Coastlands Capital Lp also recently made the following trade(s):
- On Monday, November 16th, Coastlands Capital Lp acquired 33,094 shares of Bolt Biotherapeutics stock. The shares were purchased at an average price of $5.89 per share, for a total transaction of $194,923.66.
- On Monday, November 9th, Coastlands Capital Lp acquired 50,000 shares of Bolt Biotherapeutics stock. The shares were purchased at an average price of $6.38 per share, for a total transaction of $319,000.00.
Bolt Biotherapeutics Stock Performance
Shares of NASDAQ BOLT opened at $5.65 on Wednesday. The business has a fifty day simple moving average of $4.70 and a 200 day simple moving average of $4.51. The company has a current ratio of 2.05, a quick ratio of 2.61 and a debt-to-equity ratio of 2.06. The firm has a market capitalization of $14.75 million, a price-to-earnings ratio of -0.38 and a beta of 0.85. Bolt Biotherapeutics, Inc. has a one year low of $3.10 and a one year high of $7.78.
Bolt Biotherapeutics (NASDAQ:BOLT - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($2.25) EPS for the quarter, topping the consensus estimate of ($3.68) by $1.43. Bolt Biotherapeutics had a negative return on equity of 154.11% and a negative net margin of 611.47%. The firm had revenue of $0.45 million during the quarter, compared to analysts' expectations of $0.45 million. Sell-side analysts expect that Bolt Biotherapeutics, Inc. will post -11.10 EPS for the current year.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Bolt Biotherapeutics in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $14.50.
View Our Latest Analysis on BOLT
Institutional Investors Weigh In On Bolt Biotherapeutics
A hedge fund recently raised its stake in Bolt Biotherapeutics stock. Renaissance Technologies LLC increased its position in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT - Free Report) by 40.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 77,225 shares of the company's stock after purchasing an additional 22,200 shares during the quarter. Renaissance Technologies LLC owned approximately 4.02% of Bolt Biotherapeutics worth $312,000 at the end of the most recent quarter. Institutional investors and hedge funds own 86.70% of the company's stock.
About Bolt Biotherapeutics
(
Get Free Report)
Bolt Biotherapeutics is a clinical-stage biotechnology company based in Redwood City, California. It develops immunotherapies designed to direct the body's immune system against cancer. The company's Boltbody platform is designed to pair tumor-targeting antibodies with immune-stimulating components. Its pipeline has included BDC-3042, an investigational antibody intended to activate macrophages, immune cells that can help recognize and attack tumors. Bolt has also developed BDC-1001, an investigational HER2-targeting immune-stimulating antibody conjugate.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].